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Abstract
Background: A spontaneous hepatic haemorrhage (SHH) is a rare condition that presents acutely to
both hepatobiliary and general surgeons. Management of the condition is challenging because of the
emergent presentation requiring immediate intervention, the presence of underlying chronic liver dis-
ease and the multiple potential underlying aetiological conditions.
Methods: A literature search on a spontaneous hepatic haemorrhage was instituted on Medline
(1966–2014), Cochrane Register of Controlled Trials, EMBASE (1947–2014), PubMed, Web of Science
and Google Scholar. The specific topics of interest were causes – including rare causes, pathophysio-
logical mechanisms and management options. A narrative review was planned from the outset.
Results: After 1546 abstracts were reviewed, 74 studies were chosen for inclusion. Hepatocellular
carcinoma (HCC) is the commonest cause of a spontaneous haemorrhage with 10% of HCC present-
ing with bleeding. Other causes are benign hepatic lesions (hemangioma, adenoma, focal nodular
hyperplasia, nodular regenerative hyperplasia, biliary cystadenoma and angiomyelolipoma), malignant
hepatic tumours (angiosarcoma, haemangioendothelioma, hepatoblastoma and rhabdoid sarcoma),
peliosis hepatis, amyloid, systemic lupus erythematosis, polyarteritis nodosa, HELLP syndrome and
acute fatty liver of pregnancy. Treatment practice emphasizes arterial embolization to obtain haemosta-
sis with a hepatectomy reserved for tumour-bearing patients after staging and assessment of liver
function.
Conclusion: A spontaneous hepatic haemorrhage is an acute presentation of a spectrum of condi-
tions that requires early diagnosis and multidisciplinary management.
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Introduction
A spontaneous hepatic haemorrhage (SHH) is a rare condi-
tion that results from a breach in the hepatic parenchyma
that occurs without an external cause. It is an acute surgi-
cal emergency as it results in intra-abdominal bleeding that,
if untreated, will progress to haemorrhagic shock and
death. The clinical presentation is often non-specific but
emergent, and rapid diagnosis and treatment is required,
often involving a number of services including interven-
tional radiology, hepatology and surgery. The acute man-
agement can be complex because of co-existing chronic
liver disease, and this may contribute to poor outcomes. In
spite of these issues, SHH has never been comprehensively
reviewed possibly because of its rarity, the potentially wide
range of underlying conditions and the fact that many pub-
lications in the area are small series of less than five
patients or case reports.
The aim of this investigation was to examine all the available
literature on SHH and to review comprehensively the underly-
ing pathogenesis, aetiology and management. Every attempt
was made to strike a balance between including large patient
series of conditions that are commonly associated with SHH1,2
and smaller case reports or case series that were representative
of the rarer and more obscure causes of the condition3,4 in
order to provide a comprehensive summary of the topic with
guiding principles for management.
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Material and methods
This review was structured to conform to the latest version of
the PRISMA statement and checklist.5 A literature search on a
spontaneous hepatic haemorrhage was performed on Medline
(1966–2014), Cochrane Central Register of Controlled Trials,
EMBASE (1947–2014), PubMed, Web of Science and Google
Scholar to identify published articles and conference proceed-
ings. The grey literature was assessed with a search in Google.
There were no restrictions on language and translations were
obtained where required. The search terms used were as follows:
a ‘spontaneous hepatic rupture’, ‘spontaneous liver rupture’,
‘spontaneous hepatic haemorrhage’ and ‘spontaneous liver
haemorrhage’.
Each study was reviewed by all authors. A note was made of the
numbers of patients presented, ultrastructural and anatomical find-
ings, underlying medical and surgical conditions, the treatments
employed, and the long-term results. A narrative review was
planned from the outset with no attempt at quantitative meta-anal-
ysis. A systematic review of all studies was not considered feasible
owing to the volume of case reports and small case series.
Results
The results of the search are presented in Fig. 1.
Epidemiology
A spontaneous hepatic haemorrhage is a rare condition and
was historically poorly recognized and infrequently diagnosed
in patients presenting with shock. Less than 100 cases had been
reported in the United States prior to 1980.6 However, recent
reports show that patients with SHH account for 1% of admis-
sions to specialist liver units.7,8 In areas of high prevalence of
hepatocellular carcinoma (HCC), this tumour accounts for
15% of admissions with SHH and up to 10% of all HCC pre-
sent with a spontaneous haemorrhage.7,9 In areas of low HCC
prevalence, hepatic adenoma is often the leading cause of SHH
followed by HCC, metastatic tumours, benign tumours and
connective tissue disease.8
Pathogenesis
The pathogenesis of SHH is unclear and is almost certainly
multifactorial. In patients with connective tissue disease, SHH
may result from poorly supported or weakened tissue subjected
to a trivial or a physiological event such as a fluctuation in sys-
tolic blood pressure.10 However, in tumours and tumour-like
conditions, the pathogenesis of a haemorrhage has not been
established. Importantly, SHH occurs in both large central
tumours and in small surface lesions where a haemorrhage
may occur as a result of rupture of a parasitic artery or vein
such as the inferior phrenic, traumatic laceration of a superfi-
cial tumour owing to trivial blunt abdominal trauma or from
respiratory movement. It has also been suggested that overlying
or adjacent hepatic parenchyma, particularly when affected by
cirrhosis, may split owing to pressure from tumour growth
and leading to SHH.9 Similarly, rapidly growing tumours with
central necrosis may develop an expanding central haematoma
and SHH due to compromise of the internal neovasculature.
The presence of coagulopathy may also be significant in the
initiation and maintenance of SHH although the incidence of
SHH is not increased in patients with end-stage liver failure
and refractory coagulopathy indicating that other factors must
be present for the initiation of SHH.9
A further mechanism for SHH suggests that tumour growth
(either malignant or benign) is associated with progressive
parenchymal venous obstruction owing to tissue pressure, the
development of thrombus or vascular invasion. Venous blood
is then diverted into subcapsular collaterals or the portal vein
although portal venous drainage may be compromised if portal
hypertension is present. This leads to increasing tumour con-
gestion and intratumoral pressure with eventual breach of the
hepatic capsule and development of SHH.10
There is also evidence of impairment of the vascular integ-
rity in patients presenting with SHH from HCC. Zhu et al.11
have demonstrated that in these patients von Willebrand factor
is decreased indicating the presence of endothelial injury and
compromised factor VIII function. In addition, vessels within
HCC showed proliferation of degenerated elastin, abnormal
distribution of neutrophil-associated elastase and increased
degradation of type IV collagen with associated increased levels
of collagenase around the blood vessels. Ultrastructural studies
confirm that endothelial cells adjacent to HCC show fewer cell
junctions and larger finestra.12 Collectively, these changes indi-
cate that vessels associated with SHH, in patients with HCC,
have an impaired ability to accommodate changes in blood
pressure and to resist shear forces.
These findings highlight the key difference between SHH
and a traumatic hepatic haemorrhage. In a traumatic haemor-
rhage, parenchymal disruption and breach of the Glissons cap-
sule owing to external force is the cause of a haemorrhage. In
contrast, an intra-parenchymal haemorrhage is the cause of
parenchymal and Glissons capsule rupture in SHH.13
Aetiology
The reported aetiologies for SHH are summarized in Table 1.
Collectively, a diverse group of conditions are associated with
SHH, but all are characterized by the impaired integrity of the
hepatic parenchyma and vasculature. Overall, paediatric SHH
is rare with < 50 patients reported.14 In adult patients, HCC is
the commonest cause of SHH because of its prevalence
although angiosarcoma is the tumour that is most commonly
associated with SHH as 25% will present with SHH. The risk
factors of SHH have been clarified in HCC1 and adenoma2
after multi-centre review (Table 2); however, the risk factors
for SHH pertaining to other conditions have been harder to
define primarily because of the rarity of the condition.
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Management
The management strategy for SHH is summarized in Fig. 2
and has three phases.
Diagnosis
In a contemporary series, Battula et al.51 found that over 90%
of patients present with non-specific symptoms of which
abdominal pain, malaise and vomiting were most common.
Less common presenting symptoms of haematemesis, chest
pain, fever and jaundice occurred in <10% of patients, whereas
12% of patients were shocked on admission.
A diagnosis of SHH is based on a clinical index of suspicion
in patients with a known underlying condition. However, this
is not always as straightforward as SHH is a rare complication
in patients with connective tissue disease and pregnancy. In
many patients with adenoma, SHH is the first presentation
and in patients with HCC SHH will be the first presentation in
up to 80%.15,51 In addition, up to 20% of angiosarcoma ini-
tially present with SHH.16 In rare causes, such as peliosis and
nodular regenerative hyperplasia, SHH may also be the first
presentation.51,54 Initial workup should include an assessment
of liver function, coagulation status with the emphasis on
defining and quantifying underlying hepatic function and the
presence of cirrhosis. In addition, tumour markers including
carcinoembryonic antigen, CA19-9 and alpha-fetoprotein
should also be measured. A computed tomographic (CT) scan
remains the gold standard diagnostic procedure with the find-
ing of active contrast extravasation confirming the diagno-
sis.53,64 However, over half of patients undergoing an acute CT
scan will have evidence of intrahepatic haematoma with less
than half having evidence of haemoperitoneum.51 In addition,
up to 20% of patients may be haemodynamically unstable on
arrival to hospital and proceed straight to theatre where the
diagnosis is made intra-operatively.7
Haemostasis
Obtaining durable haemostasis is the primary aim of emergent
treatment of SHH regardless of the underlying cause whereas
Type of publication Number Reference
Nationwide survey 2 1,38
Multicentre analysis 2 2,20
Non-randomized controlled trial 1 15
Literature review 3 9,43,48
Institutional series 29 7,8,11–15,17–19,21–25,27,30,32,33,35,37,39–41,48–51,58,64
Case report 37 3,4,6,10,16,26,28,29,36,42,44–46,52–57,59–63,65–75
Records identified through 
database searching
(n = 1527)
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Additional records identified 
through other sources
(n = 19)
Records after duplicates removed
(n = 1546)
Records screened
(n = 1546)
Records excluded
(n = 1362)
Full-text articles assessed 
for eligibility
(n = 184)
Full-text articles excluded: 
Lack of novel findings (n = 94)
Duplicated data (n = 5)
Incomplete data (n = 11)
Studies included in 
qualitative synthesis
(n = 74)
Studies included in 
quantitative synthesis 
(meta-analysis)
(n = 74)
Figure 1 Results of the literature search strategy and publication selection
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Table 1 Aetiological conditions associated with a spontaneous hepatic haemorrhage (SHH)
Diagnosis Frequency Associated features Risk factors for rupture Ref
Paediatric Haemangioma Five patients reported 50% have haemangiomas
at other sites (skin, lung,
laryngotracheal)
1. Large size
2. Thrombocytopenia
3. Congestive
heart failure
14
Adenoma Rare 27
Sarcoma/Rhabdoid
tumours
Rare Present between
5–10 years of age
28–31
Hepatoblastoma One third present with
SHH usually < 5 years
of age
32
HCC Rare Hepatitis B infection 33
Pregnancy
Associated
Adenoma Rare 13
HCC Rare 34
HELLP SHH in 0.015% of
deliveries
Haemolysis
Elevated transaminases
Thrombocytopenia
Present in 3rd
trimester to first
post partum week
Older, multiparous female 35–37
Acute fatty liver Two patients reported
with SHH
1 in 13 000
pregnancies
Presents 3rd trimester
with fever/jaundice
35
Malignant HCC 3–26% present
with SHH
Commonest
cause of SHH
worldwide
Associated with cirrhosis 1. Increasing tumour
diameter
2. Elevated Child-Pugh
score
3. Elevated des-c-carboxy prothrombin
4. Thrombocytopenia
5. Younger age
6. Hepatitis B infection
7. Massive tumours
rather than nodular
or diffuse
8. Exophytic tumours
1,8,17,38–41
Angiosarcoma 25% present with SHH 50% thrombocytopenic
with DIC at presentation
16,42
Haemangioendothelioma Two patients reported 4
Metastases (carcinomas
of the nasopharynx, breast,
lung, pancreas,
colon,cervix and kidney;
oesophagea leiomyosarcoma,
seminoma, granulosa cell
tumour, choriocarcinoma,
lymphoma and melanoma)
13 patients reported 62–75
Benign Adenoma Relatively common 4% adenoma > 8 cm
diameter show
malignant change
1. Diameter > 5 cm
2. Hormone use
within 6 months
2,43
FNH 10 patients reported No relation to lesion diameter 44–46
Haemangioma 46 patients reported 1. No relation to lesion diameter
2. Rare > 65 years of age
47,48
Nodular Regenerative
Hypeplasia
Four patients reported Present in 2.5% of
autopsies but SHH rare
49–51
Cystadenoma One patient reported 52
Angiomyelolipoma One patient reported 53
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in patients with an underlying tumour, subsequent definitive
oncological treatment will need to be considered.
The published methods for obtaining haemostasis are sum-
marized in Table 2. The majority of the published
series7,8,15,19–24,38,39,41,51 include patients with SHH owing to
HCC as this condition has the highest worldwide prevalence,
and it is important to emphasize that the treatment groups
cannot be directly compared. Many of these patients have
advanced underlying cirrhosis or fibrosis and are preferentially
managed non-operatively either with conservative management
or embolization alone. In advanced cases only palliative care is
provided. However, in spite of this a number of conclusions
can be drawn. Conservative therapy (defined as active resusci-
tation with blood product replacement) results in control of
bleeding in almost half of the patients.15 In those that continue
to bleed or rebleed, bland embolization is effective in obtaining
haemostasis in almost 80%.20 However, Liu et al.24 emphasize
that the procedure is not always feasible in up to 20% of
patients (11 of 53 cases in their series) owing to technical
issues including thrombosis of the main portal vein, arteriove-
nous shunting and technical failure including dissection. Zhu
et al.9 also emphasize that acute embolization should be under-
taken with gel foam rather than coils to facilitate later
chemoembolization as a primary treatment and that a selective
or subselective approach is optimal in addressing collateral cir-
culation to tumours and optimizing post-procedure hepatic
Table 1 Continued
Diagnosis Frequency Associated features Risk factors for rupture Ref
Vascular Peliosis hepatis Two patients reported 54,55
Connective
tissue disease
Amyloid 11 patients reported Hepatomegally
with vascular fagility
is common
3,10,56
SLE SHH rare but
hepatomegally
present in in
20% of SLE patients
Hepatic necrosis
with fibrinoid necrosis
of hepatic arterial
branches
57
Polyarteritis nodosa 10 patients reported Hepatic infarction
and cirrhosis may
also present
Aneuysm of intrahepatic
arteries present
in 60% of patients
58,59
Miscellaneous Vomiting Single report only 60
Warfarin therapy Single report only 61
HCC, hepatocellular carcinoma; HELLP, haemolysis, elevated liver enzymes, low platelets; FNH, focal nodular hyperplasia; SLE, systemic lupus
erythematosis.
Table 2 Summary of haemostatic treatments for a spontaneous hepatic haemorrhage. The first set of parentheses indicates the number
of patients with bleeding successfully controlled, the second set indicates the number surviving at 1 month after treatment and the third
set indicates the number surviving at 1 year after treatment
Reference Year Conservative TAE HAL Segmental HAL Packing/Plication Resection
Chearanai39 1983 27 (7) (4) (0) 26 (24) (0) (0) 9 (0) (0) (0) 1 (1) (1) (0)
Lai21 1989 4 (–) (–) (–) 39 (28) (16) (9) 8 (4) (4) (1) 2 (2) (1) (1) 7 (5) (4) (1)
Miyamoto38 1991 14 (4) (4) (0) 57 (40) (40) (17) 10 (10) (4) (0) 30 (28) (11) (2) 31 (31) (23) (13)
[Delayed Hepatectomy
1 (21) (21) (15)]
Dewar7 1991 2 (0) (0) (0) 4 (4) (0) (0) 12 (8) (3) (0) 8 (6) (2) (0) 11 (5) (4) (0)
Cherqui22 1993 1 (0) (0) (0) 4 (4) (3) (1)
Xu19 1994 68 (35) (35) (1) 9 (9) (3) (1) 7 (7) (2) (–) 2 (2) (2) (2)
Chiappa23 1999 6 (6) (4) (3)
Liu24 2001 67 (44) (–) (–) 42 (35) (25) (0) 23 (23) (–) (–) 8 (8) (–) (–) 2 (2) (–) (–)
Kirikoshi20 2009 32 (16) (2) (–) 16 (15) (15) (7)
Battula8 2009 7 (5) (–) (–) 6 (6) (–) (–) 1 (1) (–) (–)
Battula51 2012 44 (32) (32) (30) 4 (4) (–) (–) 2 (1) (0) (0) 11 (7) (5) (5)
Total 244 (158) (77) (31) 130 (99) (80) (24) 120 (92) (26) (10) 8 (4) (4) (1) 72 (58) (16) (3) 76 (64) (46) (25)
(–), not reported; TAE, transarterial embolization; HAL, hepatic artery ligation.
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function. Liu et al.24 have described acute treatment with
chemoembolization (TACE) in patients with HCC with similar
rates of haemostasis to bland embolization; however, few insti-
tutions can provide TACE acutely.
Up to 20% of patients undergoing embolization will require
surgical intervention to achieve haemostasis owing to persistent
or recurrent bleeding and in some patient groups (paediatric14
and pregnant patients35) an initial radiological approach may
not be possible. In addition, up to 20% of patients with SHH
will be haemodynamically unstable at presentation and will
proceed directly to a laparotomy where the diagnosis will be
made intra-operatively. For these patients, plication and pack-
ing will achieve haemostasis in one-third, and this increases to
two-thirds if combined with ipsilateral hepatic artery ligation
(HAL).9 The majority of series reporting hepatic artery ligation
utilize ligation of either the left or right main artery.21,39 Lai
et al.21 have also assessed selective ligation of segmental arteries
to the tumour-bearing liver and have found similar haemo-
static results to main artery ligation. However, segmental liga-
tion is more technically challenging than main artery ligation,
particularly for the non-hepatobiliary surgeon, but may facili-
tate later a parenchymal-sparing resection. It is important to
emphasize that HAL and embolization have similar haemo-
static efficacy but, at least in patients with bleeding HCC, the
mortality rate at 1 month post procedure is higher after HAL
owing to hepatic failure.9,24
Contemporary results of an acute hepatic resection are
encouraging. However, many series include resection for
benign adenoma51 and the HCC patients selected for this
approach are well compensated, have minimal underlying liver
disease and small peripheral tumours that can be treated with
small local or segmental resections rather than a major hepate-
ctomy.38 In general, a hepatic resection is not undertaken
acutely with the sole aim of obtaining haemostasis. Liu et al.24
Initial assessment
Clinical history, examination, check full blood count, urea, creatinine, 
electrolytes, liver function tests, coagulation, tumour markers
Haemodynamically stable?
CT scan with contrast
(Consider MRI or US in pregnant or 
paediatric patients)
Patient suitable for active treatment Symptomatic care
Urgent transfer 
operating suite
Plication/hepatic 
packing
Hepatic artery 
ligation
Suitable for TAE
Haemostasis achieved
Clinical assessment, staging 
and multidisciplinary review 
for definitive treatment
Ablation
Resection
TACE
Surveillance
Conservative 
management
Conservative management 
successful?
No
Yes
No
Yes
No active
bleeding
Active bleeding
No
Yes
Yes
No
TAE
Figure 2 Management algorithm for a spontaneous hepatic haemorrhage. CT Scan, computed tomographic scan; MRI, magnetic
resonance scan; US, ultrasound scan; TAE, transarterial embolization; TACE, transarterial chemoembolization
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have also described the acute intra-operative injection of alco-
hol and ablation of bleeding HCC to obtain successfully
haemostasis.
Definitive treatment
Patients presenting with SHH from hepatic malignancy, in
whom haemostasis has been achieved, will require assessment
for definitive oncological treatment. This group is made up of
primarily patients with HCC. Overall, 40% of these patients
come forward for resection, ablation or TACE after assessment
of hepatic function and staging.24,51 A hepatic resection in this
group is generally carried out between 1 and 6 weeks after
haemostatic therapy and associated with a morbidity rate of
40% and a mortality rate of 9%.24 The results described by
Miyamoto et al.38 emphasize the improved outcome achieved
with delayed rather than acute hepatectomy for HCC
(Table 2). Similar results have been described for definitive
treatment with TACE and radiofrequency ablation8 and a
number of investigators have shown that the outcome for
patients with SHH and HCC is dependent on the severity of
cirrhosis, the admission plasma bilirubin concentration and
severity of shock on admission rather than the definitive treat-
ment employed.20,24,40
Overall, the outcome after haemostasis for SHH is wholly
dependent on the underlying pathology. Battula et al.51 report
a zero mortality rate in patients presenting with benign
tumours (adenoma, focal nodular hyperplasia and haeman-
giomata) as well as polyarteritis whereas in patients with HCC,
40% died within 12 months of treatment with 20% dying
within 1 week of presentation. However, the highest mortality
was seen with SHH as a result of HELLP syndrome with 75%
dying during their index admission primarily owing to liver
failure from hepatic necrosis. In these patients, an initial oper-
ative approach is often necessary as an acute Caesarean section
can be indicated for fetal distress, and early radiological
embolization is not feasible. This is only the condition where
acute liver transplantation has been described to treat SHH
and the associated hepatic failure.35
Summary
SHH is a rare event most commonly caused by HCC and hep-
atic adenoma although there are numerous other causative
lesions including all recognized benign and malignant hepatic
tumours including metastatic cancer. The mechanism of spon-
taneous bleeding remains unclear but there is evidence for
compromised vascular integrity at least in patients with HCC
and the incidence of the condition in patients with connective
tissue diseases (amyloid and SLE) and polyarteritis nodosa
indicates that this is an important factor in the pathogenesis of
the condition. Cross-sectional imaging with CT scanning is the
mainstay of diagnosis and initial management emphasizes
the use of arterial embolization to obtain haemostasis with a
hepatectomy reserved for patients with bleeding tumours after
formal staging and assessment of their liver function.
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